Edwards Lifesciences Corp (EW): Larry L Wood , CVP, THV Replacement of Edwards Lifesciences Corp sold 13,257 shares on Jul 1, 2016. The Insider selling transaction was reported by the company on Jul 5, 2016 to the Securities and Exchange Commission. The shares were sold at $99.13 per share for a total value of $1,309,611.50 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 9, 2016, Michael A Mussallem (Chairman & CEO) sold 49,100 shares at $102.25 per share price.On Jun 7, 2016, Huimin Wang (CVP, Japan & Intercontinental) sold 13,650 shares at $101.50 per share price.Also, On Jun 6, 2016, Larry L Wood (CVP, THV Replacement) sold 13,257 shares at $101.34 per share price.On Jun 2, 2016, Donald E Jr Bobo (CVP, Heart Valve Therapy) sold 18,000 shares at $99.41 per share price.
Shares of Edwards Lifesciences Corp (EW) ended Friday, Jul 1, 2016 session in red amid volatile trading. The shares closed down -1.15 points or -1.15% at $98.58 with 12,71,497 shares getting traded. Post opening the session at $99.83, the shares hit an intraday low of $98.28 and an intraday high of $99.83 and the price vacillated in this range throughout the day. The company has a market cap of $20,876 M and the number of outstanding shares has been calculated to be 21,17,62,740 shares. The 52-week high of Edwards Lifesciences Corp is $112 and the 52-week low is $62.53.
Company has been under the radar of several Street Analysts.Edwards Lifesciences Corp is Initiated by Guggenheim to Neutral. The Rating was issued on Jun 9, 2016.Edwards Lifesciences Corp is Reiterated by Canaccord Genuity to Buy and the brokerage firm has raised the Price Target to $ 132 from a previous price target of $123 .The Rating was issued on May 23, 2016.Edwards Lifesciences Corp is Reiterated by RBC Capital Mkts to Outperform and the brokerage firm has raised the Price Target to $ 125 from a previous price target of $110 .The Rating was issued on Apr 27, 2016.Edwards Lifesciences Corp is Reiterated by Canaccord Genuity to Buy and the brokerage firm has raised the Price Target to $ 123 from a previous price target of $113 .The Rating was issued on Apr 27, 2016.
Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.